Get the Stockscreener App
0.5449
54.21%
-0.6451
After Hours:
.55
0.0051
+0.94%
Aspire Biopharma Holdings Inc stock is traded at $0.5449, with a volume of 5.07M.
It is down -54.21% in the last 24 hours and down -48.10% over the past month.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
See More
Previous Close:
$1.19
Open:
$0.9312
24h Volume:
5.07M
Relative Volume:
6.05
Market Cap:
$2.74M
Revenue:
$6,200
Net Income/Loss:
$-24.48M
P/E Ratio:
-0.1123
EPS:
-4.8539
Net Cash Flow:
$-4.92M
1W Performance:
-54.21%
1M Performance:
-48.10%
6M Performance:
-96.04%
1Y Performance:
-97.52%
1-Day Range:
$0.52
$0.9312
1-Week Range:
$0.52
$1.245
52-Week Range:
$0.52
$35.01
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.5449 | 5.98M | 6,200 | -24.48M | -4.92M | -4.8539 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma's Buzz Bomb Caffeine Brand Partners with Interwest Brokerage - National Today
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Aspire Biopharma Holdings, Inc. Announces LOI to Acquire Driver Controls Systems Business from Firefish Topco LLC - Minichart
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion - USA Today
Buzz Bomb targets Utah, Idaho, Montana stores via Interwest deal - Stock Titan
Aspire Biopharma Signs LOI to Acquire DCS Unit - TipRanks
Aspire Biopharma signs non-binding letter of intent to acquire DCS unit - Investing.com
Aspire Biopharma Signs LOI to Acquire Driver Controls Systems for $30 Million - TradingView — Track All Markets
Aspire Biopharma (ASBP) signs non-binding $30M deal for DCS unit - Stock Titan
[EFFECT] Aspire Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Peoria Journal Star
ASBP Stock Price, Quote & Chart | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Bluffton Today
Aspire Biopharma Provides Q3 2025 Business Update - The Augusta Chronicle
Aspire Biopharma secures up to $21M in convertible preferred stock financing - MSN
159M ASBP (Nasdaq: ASBP) resale shares tied to $20M preferred deal - Stock Titan
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack - Pocono Record
Aspire Biopharma Holdings: Innovative Patent-Pending Sublingual Drug Delivery & Product Pipeline Overview - Minichart
Aspire Biopharma (NASDAQ: ASBP) details sublingual pipeline and financings - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - The Times Telegram
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Visalia Times-Delta
ASBP Technical Analysis | Trend, Signals & Chart Patterns | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 - patriotledger.com
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Burlington Free Press
Aspire Biopharma: Disruptive Sublingual Drug Delivery Technology, Pipeline, and Patent Portfolio Overview 798289 - Minichart
Aspire Biopharma 10-K: Revenue $6.2K, Net Loss $24.48M - TradingView — Track All Markets
Reverse recap and sublingual pipeline reshape Aspire Biopharma (NASDAQ: ASBP) - Stock Titan
Aspire Biopharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - The Patriot Ledger
ASBP Soars: Biotech Turbulence Fuels an Unexpected 17% Jump - bitget.com
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director - ACCESS Newswire
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion - Black Hills Pioneer
Aspire Biopharma's Subsidiary Announces Retail Expansion Deal - National Today
Aspire Biopharma Plunges 19.5% on Intraday Freefall: What’s Fueling the Sharp Drop? - Bitget
Aspire subsidiary names John Choe as western sales director By Investing.com - Investing.com South Africa
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):